乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

GuCS

<乌鸦传媒>Enfortumab Vedotin Promising in Neovadjuvant Therapy in Advanced Bladder Cancer

Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease

<乌鸦传媒>Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer

Docetaxel-enzalutamide regimen may offer another option for men who progressed on AR inhibitor

<乌鸦传媒>Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC

In one case, rPFS benefit was seen regardless of HRR mutational status

<乌鸦传媒>Darolutamide Improves OS in Metastatic Prostate Cancer

The AR inhibitor plus standard therapy led to a 32% reduced risk of death versus placebo

<乌鸦传媒>A CLEAR Upfront Winner in Advanced RCC?

Pembrolizumab-lenvatinib makes splash with longest PFS benefit in RCC recorded to date

<乌鸦传媒>Practice-Changing Trial in Metastatic Papillary RCC

Cabozantinib improved PFS, response rates over sunitinib

<乌鸦传媒>New Standard in High-Risk Muscle-Invasive Bladder Cancer?

Adjuvant nivolumab improves DFS in all comers, PD-L1 population

<乌鸦传媒>CCR Score Could Offer ADT-Free Path in Higher-Risk Prostate Cancer

Large proportion of intermediate- to high-risk patients could avoid aggressive therapy

<乌鸦传媒>Survival Boost in Bladder Cancer With Antibody-Drug Conjugate

Four-month absolute improvement with enfortumab vedotin in previously treated disease

<乌鸦传媒>Radionuclide Tx Wins in Third-Line Metastatic CRPC

Early trial shows improved PFS, response rates versus cabazitaxel

<乌鸦传媒>Hit and Miss in Castration-Resistant Prostate Cancer

No OS benefit with apalutamide-abiraterone, despite improved PFS

<乌鸦传媒>No Survival Bump Yet with Tivozanib for RCC

Selected studies on kidney cancer from the Genitourinary Cancers Symposium

<乌鸦传媒>'Encouraging' Early Data with Keytruda in High-Risk Bladder Ca

Will responses in non-muscle-invasive, BCG-unresponsive disease prove durable?

<乌鸦传媒>Bladder Ca Treatment Enters 'Post-Checkpoint' Era

Early trials show responses with antibody-drug conjugates

<乌鸦传媒>Doubling Down on Antiandrogens Improves PFS in Metastatic Prostate Ca

But lack of OS data for enzalutamide-ADT may hold it back

<乌鸦传媒>Immunotherapy Lurches Forward in Prostate Cancer

Combination trials in mCRPC yield responses in immunologically "cold" tumor

<乌鸦传媒>Surveillance of Low-Risk Prostate Cancer Tripled

Radical prostatectomy gained some ground for high-risk disease

<乌鸦传媒>Radiological Agent Shows Promise in Heavily Treated mCRPC

PSA decline of 50% or greater in two-thirds of patients

<乌鸦传媒>Better Survival for African-Americans With mCRPC

Significant improvement vs whites with androgen-directed agents

<乌鸦传媒>Survival Bump in Bladder Cancer with Keytruda

But no outcome advantage for Tecentriq in metastatic urothelial cancer

<乌鸦传媒>Time to Metastasis Prolonged in Castration-Resistant Prostate Ca

Researchers found a 22-month improvement with enzalutamide

<乌鸦传媒>Apalutamide Slows Metastasis in Prostate Cancer

Two-year delay in metastatic progression with apalutamide

<乌鸦传媒>Gene Therapy Moves Ahead in Urothelial Cancer

Complete response in 35% of BCG-treated patients at 12 months

<乌鸦传媒>'Jurassic' Clinical Trial Yields Prostate Cancer Guidance

Negative trial informs new studies of adjuvant therapy

<乌鸦传媒>Cancer Drugs' Benefit Continues After Drug Stopped

Response for as long as 20 months after PD-1/PD-L1 stopped

<乌鸦传媒>Antibiotics May Damper Effect of PD-1/PD-L1 Blockade

Worse PFS in metastatic renal cell carcinoma

<乌鸦传媒>No DFS Benefit With Chemoradiation in Bladder Cancer

Adjuvant combo reduces local recurrence after cystectomy

<乌鸦传媒>Adding Hormonal Tx To Salvage RT Ups Prostate Ca Survival

Metastasis, cancer-specific survival also reduced in high-risk disease

<乌鸦传媒>Lower-Dose RT New Standard for Prostate Cancer?

Non-inferiority demonstrated for 60 Gy versus 74 Gy

<乌鸦传媒>Aspirin May Lower Risk of Lethal Prostate Cancer

But confirmation needed before a firm recommendation can be made

<乌鸦传媒>Seeds Top EBRT as Boost Tx in Prostate Cancer

And other advances in prostate cancer care from the Genitourinary Cancers Symposium.

<乌鸦传媒>Zytiga Prolongs Prostate Cancer Survival

ORLANDO -- Survival improved and disease progression slowed in men with metastatic castration-resistant prostate cancer treated in first line with abiraterone acetate (Zytiga).

<乌鸦传媒>Steroids Reduce Benefits of Prostate Ca Tx

ORLANDO -- Men with castration-resistant prostate cancer had worse survival when treated with corticosteroids, regardless of their primary treatment, a post-hoc analysis of a randomized trial showed.

<乌鸦传媒>Early Radiation Boosts Prostate Cancer Survival

ORLANDO -- Immediate radiation therapy after radical prostatectomy led to a 50% increase in long-term biochemical progression-free survival for patients with locally advanced prostate cancer, according to a study reported here.